Biological and Pharmaceutical Bulletin
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 18,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Ken-ichi Hosoya
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama



Read more
9,441 registered articles
(updated on April 24, 2018)
Online ISSN : 1347-5215
Print ISSN : 0918-6158
1.683
2016 IMPACT FACTOR
JOURNALS PEER REVIEWED FREE ACCESS FULL-TEXT HTML ADVANCE PUBLICATION
Featured article
Volume 41 (2018) Issue 4 Pages 612-618
Virion-Packaged Pyruvate Kinase Muscle Type 2 Affects Reverse Transcription Efficiency of Human Immunodeficiency Virus Type 1 by Blocking Virion Recruitment of tRNALys3 Read more
Editor’s picks

Human immunodeficiency virus type 1 (HIV-1) recruits diverse cellular factors into viral particles during its morphogenesis, which apparently play roles in modulating its infectivity. The article by Mouree et al. evaluated that a key glycolytic protein, pyruvate kinase muscle type 2 (PKM2) is incorporated into viral particles. Furthermore, the virion-packaged PKM2 significantly reduces the viral infectivity by affecting the selective packaging of intravirion tRNALys3, which primes the initiation of reverse transcription, along with other nonpriming tRNAs, such as tRNALys1,2 and tRNAAsn, without affecting the cytoplasmic level of these tRNAs. These findings proposed that PKM2 is a vital host factor that negatively affects HIV-1 infectivity by targeting the tRNALys3-mediated initiation of reverse transcription in target cells.

View the past featured articles
View all articles in Current issue
Most viewed articles Mar.2018
Share this page
Select past volume & issue
Journal news & Announcements
  • Biol. Pharm. Bull. Vol. 41 No. 3
    Current Topics: Cutting-Edge Studies Using Artificial Membranes
  • Biol. Pharm. Bull. Vol. 40 No. 12
    Current Topics: Recent Progress in the Study of Vasoactive Modulators in Metabolic and Cardiovascular Diseases



feedback
Top